世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

MEAリキッドバイオプシー市場 - 2030年までの産業動向と予測


MEA Liquid Biopsy Market - Industry Trends and Forecast to 2030

中東・アフリカのリキッドバイオプシー市場は、2022年の5,398万米ドルから2030年には1億2,247万米ドルに達し、2023年から2030年の予測期間中に年平均成長率11.7％で成長すると予測される。 市場細分化： 中東... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年5月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		267 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

中東・アフリカのリキッドバイオプシー市場は、2022年の5,398万米ドルから2030年には1億2,247万米ドルに達し、2023年から2030年の予測期間中に年平均成長率11.7％で成長すると予測される。

市場細分化：
中東・アフリカのリキッドバイオプシー市場：製品別（装置、消耗品・アクセサリー、サービス・ソフトウェア）、バイオマーカータイプ別（循環腫瘍細胞（CTCS）、循環無細胞DNA（CFDNA）、無細胞RNA、細胞外小胞、エクソソーム、その他）、サンプルタイプ（血液サンプルベース、尿サンプルベース、唾液・その他組織液サンプルベース、その他）、分析タイプ（分子、プロテオミクス、組織・画像）、アプリケーションタイプ（がんアプリケーション、非がんアプリケーション）、臨床アプリケーション（ルーチンスクリーニング、患者ワークアップ、治療法選択、治療モニタリング、再発モニタリング、その他）、技術（マルチ遺伝子並列分析、単一遺伝子分析）、エンドユーザー（病院、リファレンスラボ、診断センター、研究センター・学術機関、その他）、流通チャネル（直接入札、第三者販売代理店、その他）、国（サウジアラビア、南アフリカ、UAE、イスラエル、エジプト、クウェート、カタール、ナイジェリア、その他の中東・アフリカ）産業動向と2030年までの予測

中東・アフリカのリキッドバイオプシー市場動向の概要：

ドライバー

- リキッドバイオプシー・プラットフォームの技術的進歩

阻害要因
- 標準化されたガイドラインの欠如
機会

- リキッドバイオプシーに対する償還金と政府支援の増加
市場プレイヤー

中東・アフリカのリキッドバイオプシー市場で事業を展開する主要な市場プレーヤーを以下に挙げる：

- F.ホフマン・ラ・ロシュ社
- サーモフィッシャーサイエンティフィック
- イグザクト・サイエンシズ・コーポレーション（ゲノムヘルス）
- QIAGEN
- ラボコープ
- ジョンソン・エンド・ジョンソンサービス社
- イルミナ社
- バイオ・ラッド・ラボラトリーズ社
- ナテラ社
- カーディフオンコロジー社
- シスメックス・イノスティクス社




ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 60
1.4 LIMITATIONS 62
1.5 MARKETS COVERED 62
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 MULTIVARIATE MODELLING 72
2.7 PRODUCT TYPE LIFELINE CURVE 72
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.9 DBMR MARKET POSITION GRID 74
2.10 MARKET TESTING TYPE COVERAGE GRID 75
2.11 VENDOR SHARE ANALYSIS 76
2.12 SECONDARY SOURCES 77
2.13 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 81
4.1 PESTEL ANALYSIS 82
4.2 PORTER’S FIVE FORCES 83
5 INDUSTRY INSIGHTS: 84
6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, REGULATION 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE 89
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY 90
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS 91
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS 92
7.2 RESTRAINTS 93
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS 93
7.2.2 LACK OF STANDARDIZED GUIDELINES 94
7.3 OPPORTUNITIES 95
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING 95
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY 96
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES 96
7.4 CHALLENGES 97
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY 97
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES 98
8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT 99
8.1 OVERVIEW 100
8.2 CONSUMABLES & ACCESSORIES 103
8.2.1 TEST KITS 104
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT 104
8.2.1.2 DNA ISOLATION KIT 104
8.2.1.3 OTHERS 104
8.2.2 COLLECTION TUBES 104
8.2.2.1 50 PIECES 105
8.2.2.2 100 PIECES 105
8.2.3 ASSAYS 105
8.2.3.1 FLEXIBLE REAGENTS 105
8.2.3.2 SCALABLE REAGENTS 105
8.2.3.3 OTHERS 105
8.2.4 CONTROL KIT 105
8.2.5 OTHERS 105
8.3 INSTRUMENTS 105
8.3.1 ANALYZERS 106
8.3.2 SYSTEMS 106
8.3.3 OTHERS 107
8.4 SERVICES & SOFTWARE 107
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE 108
8.4.2 DPCR ANALYSIS SOFTWARE 108
8.4.3 CASTPCR ANALYSIS SOFTWARE 108
8.4.4 OTHERS 108
9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE 109
9.1 OVERVIEW 110
9.2 CIRCULATING TUMOR CELLS (CTCS) 113
9.3 CIRCULATING CELL-FREE DNA (CFDNA) 114
9.4 CELL-FREE RNA 115
9.5 EXOSOMES 116
9.6 EXTRACELLULAR VESICLES 117
9.7 OTHERS 118
10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE 119
10.1 OVERVIEW 120
10.2 BLOOD SAMPLE-BASED 123
10.3 URINE SAMPLE-BASED 124
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED 125
10.5 OTHERS 126
11 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE 127
11.1 OVERVIEW 128
11.2 MOLECULAR 131
11.2.1 NGS 132
11.2.2 PCR 132
11.2.3 MICROARRAY 132
11.2.4 PROTEOMICS 132
11.2.5 OTHERS 132
11.3 PROTEOMIC 132
11.3.1 NGS 133
11.3.2 PCR 133
11.3.3 MICROARRAY 133
11.3.4 PROTEOMICS 133
11.3.5 OTHERS 133
11.4 HISTOLOGY/IMAGING 134
12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE 135
12.1 OVERVIEW 136
12.2 CANCER APPLICATIONS 139
12.2.1 LUNG 140
12.2.2 BREAST 140
12.2.2.1 EARLY BREAST CANCER 140
12.2.2.2 ADVANCED BREAST CANCER 140
12.2.3 COLORECTAL 140
12.2.4 PROSTRATE 141
12.2.5 LIVER 141
12.2.6 OTHERS 141
12.3 NON-CANCER APPLICATIONS 141
12.3.1 PRENATAL DIAGNOSIS 142
12.3.2 PERSONALIZED IMMUNOTHERAPY 142
12.3.3 OTHERS 142
13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 143
13.1 OVERVIEW 144
13.2 ROUTINE SCREENING 147
13.3 THERAPY SELECTION 148
13.4 TREATMENT MONITORING 148
13.4.1 EARLY-STAGE DISEASE 149
13.4.2 LATE-STAGE/METASTATIC DISEASE 149
13.5 RECURRENCE MONITORING 150
13.6 PATIENT WORK-UP 150
13.7 OTHERS 151
14 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY 152
14.1 OVERVIEW 153
14.2 MULTI-GENE-PARALLEL ANALYSIS 156
14.3 SINGLE GENE ANALYSIS 157
15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER 158
15.1 OVERVIEW 159
15.2 HOSPITALS 162
15.3 REFERENCE LABORATORIES 162
15.4 DIAGNOSTIC CENTERS 163
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES 163
15.6 OTHERS 165
16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL 166
16.1 OVERVIEW 167
16.2 DIRECT TENDER 170
16.3 THIRD PARTY DISTRIBUTOR 170
16.4 OTHERS 171
17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY REGION 172
17.1 MIDDLE EAST AND AFRICA 173
17.1.1 SOUTH AFRICA 185
17.1.2 SAUDI ARABIA 192
17.1.3 U.A.E. 199
17.1.4 EGYPT 206
17.1.5 ISRAEL 213
17.1.6 REST OF MIDDLE EAST AND AFRICA 220
18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE 221
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 221
19 COMPANY PROFILE 222
19.1 F. HOFFMANN-LA ROCHE LTD. 222
19.1.1 COMPANY SNAPSHOT 222
19.1.2 REVENUE ANALYSIS 222
19.1.3 COMPANY SHARE ANALYSIS 223
19.1.4 PRODUCT PORTFOLIO 223
19.1.5 RECENT DEVELOPMENTS 223
19.2 GUARDANT HEALTH 224
19.2.1 COMPANY SNAPSHOT 224
19.2.2 REVENUE ANALYSIS 224
19.2.3 COMPANY SHARE ANALYSIS 225
19.2.4 PRODUCT PORTFOLIO 225
19.2.5 RECENT DEVELOPMENTS 225
19.3 THERMO FISHER SCIENTIFIC INC. 226
19.3.1 COMPANY SNAPSHOT 226
19.3.2 REVENUE ANALYSIS 226
19.3.3 COMPANY SHARE ANALYSIS 227
19.3.4 SWOT ANALYSIS 227
19.3.5 PRODUCT PORTFOLIO 228
19.3.6 RECENT DEVELOPMENTS 229
19.4 EXACT SCIENCE CORPORATION 230
19.4.1 COMPANY SNAPSHOT 230
19.4.2 REVENUE ANALYSIS 230
19.4.3 COMPANY SHARE ANALYSIS 231
19.4.4 PRODUCT PORTFOLIO 231
19.4.5 RECENT DEVELOPMENTS 231
19.5 QIAGEN 232
19.5.1 COMPANY SNAPSHOT 232
19.5.2 REVENUE ANALYSIS 232
19.5.3 COMPANY SHARE ANALYSIS 233
19.5.4 PRODUCT PORTFOLIO 233
19.5.5 RECENT DEVELOPMENTS 234
19.6 ANGLE PLC (2022) 235
19.6.1 COMPANY SNAPSHOT 235
19.6.2 REVENUE ANALYSIS 235
19.6.3 PRODUCT PORTFOLIO 236
19.6.4 RECENT DEVELOPMENT 236
19.7 BIOCEPT, INC. 237
19.7.1 COMPANY SNAPSHOT 237
19.7.2 REVENUE ANALYSIS 237
19.7.3 PRODUCT PORTFOLIO 238
19.7.4 RECENT DEVELOPMENT 238
19.8 BIO-RAD LABORATORIES, INC. (2022) 239
19.8.1 COMPANY SNAPSHOT 239
19.8.2 REVENUE ANALYSIS 239
19.8.3 PRODUCT PORTFOLIO 240
19.8.4 RECENT DEVELOPMENTS 240
19.9 EPIC SCIENCES 241
19.9.1 COMPANY SNAPSHOT 241
19.9.2 PRODUCT PORTFOLIO 241
19.9.3 RECENT DEVELOPMENTS 241
19.10 FLUXION BIOSCIENCES INC 242
19.10.1 COMPANY SNAPSHOT 242
19.10.2 PRODUCT PORTFOLIO 242
19.10.3 RECENT DEVELOPMENTS 242
19.11 ILLUMINA, INC. 243
19.11.1 COMPANY SNAPSHOT 243
19.11.2 REVENUE ANALYSIS 243
19.11.3 SWOT ANALYSIS 244
19.11.4 PRODUCT PORTFOLIO 244
19.11.5 RECENT DEVELOPMENT 244
19.12 JOHNSON & JOHNSON PRIVATE LIMITED 246
19.12.1 COMPANY SNAPSHOT 246
19.12.2 REVENUE ANALYSIS 246
19.12.3 SWOT ANALYSIS 247
19.12.4 PRODUCT PORTFOLIO 247
19.12.5 RECENT DEVELOPMENTS 247
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS 248
19.13.1 COMPANY SNAPSHOT 248
19.13.2 REVENUE ANALYSIS 248
19.13.3 SWOT ANALYSIS 249
19.13.4 PRODUCT PORTFOLIO 249
19.13.5 RECENT DEVELOPMENT 249
19.14 MDXHEALTH 250
19.14.1 COMPANY SNAPSHOT 250
19.14.2 REVENUE ANALYSIS 250
19.14.3 PRODUCT PORTFOLIO 251
19.14.4 RECENT DEVELOPMENTS 251
19.15 MENARINI SILICON BIOSYSTEMS 252
19.15.1 COMPANY SNAPSHOT 252
19.15.2 PRODUCT PORTFOLIO 252
19.15.3 RECENT DEVELOPMENTS 252
19.16 NATERA, INC. 253
19.16.1 COMPANY SNAPSHOT 253
19.16.2 REVENUE ANALYSIS 253
19.16.3 PRODUCT PORTFOLIO 254
19.16.4 RECENT DEVELOPMENTS 254
19.17 NEOGENOMICS LABORATORIES 255
19.17.1 COMPANY SNAPSHOT 255
19.17.2 REVENUE ANALYSIS 255
19.17.3 PRODUCT PORTFOLIO 256
19.17.4 RECENT DEVELOPMENTS 256
19.18 ONCOCYTE CORPORATION 257
19.18.1 COMPANY PROFILE 257
19.18.2 SERVICE PORTFOLIO 257
19.18.3 RECENT DEVELOPMENTS 257
19.19 PATHAI 258
19.19.1 COMPANY SNAPSHOT 258
19.19.2 PRODUCT PORTFOLIO 258
19.19.3 RECENT DEVELOPMENTS 258

　

ページTOPに戻る


　

Summary

The Middle East and Africa liquid biopsy market is expected to reach USD 122.47 million by 2030 from USD 53.98 million in 2022, growing at a CAGR of 11.7% during the forecast period of 2023 to 2030.

Market Segmentation:
Middle East and Africa Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomarker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample Based, Urine Sample Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others), Country (Saudi Arabia, South Africa, UAE, Israel, Egypt, Kuwait, Qatar, Nigeria, and the Rest of the Middle East and Africa) Industry Trends and Forecast to 2030

Overview of Middle-East and Africa liquid biopsy market Dynamics :

Driver

• Technological advancements in liquid biopsy platforms

Restrain
• Lack of standardized guidelines
Opportunity

• Increasing reimbursements and government support for liquid biopsy
Market Players:

Some of the key market players operating in the Middle East and Africa liquid biopsy market are listed below:

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Exact Sciences Corporation (Genomic health)
• QIAGEN
• Labcorp
• Johnson & Johnson Services, Inc.
• Illumina Inc
• Bio-Rad Laboratories, Inc.
• Natera, Inc.
• CARDIFF ONCOLOGY, INC.
• Sysmex Inostics Inc.




ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 60
1.4 LIMITATIONS 62
1.5 MARKETS COVERED 62
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 MULTIVARIATE MODELLING 72
2.7 PRODUCT TYPE LIFELINE CURVE 72
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.9 DBMR MARKET POSITION GRID 74
2.10 MARKET TESTING TYPE COVERAGE GRID 75
2.11 VENDOR SHARE ANALYSIS 76
2.12 SECONDARY SOURCES 77
2.13 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 81
4.1 PESTEL ANALYSIS 82
4.2 PORTER’S FIVE FORCES 83
5 INDUSTRY INSIGHTS: 84
6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, REGULATION 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE 89
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY 90
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS 91
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS 92
7.2 RESTRAINTS 93
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS 93
7.2.2 LACK OF STANDARDIZED GUIDELINES 94
7.3 OPPORTUNITIES 95
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING 95
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY 96
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES 96
7.4 CHALLENGES 97
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY 97
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES 98
8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT 99
8.1 OVERVIEW 100
8.2 CONSUMABLES & ACCESSORIES 103
8.2.1 TEST KITS 104
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT 104
8.2.1.2 DNA ISOLATION KIT 104
8.2.1.3 OTHERS 104
8.2.2 COLLECTION TUBES 104
8.2.2.1 50 PIECES 105
8.2.2.2 100 PIECES 105
8.2.3 ASSAYS 105
8.2.3.1 FLEXIBLE REAGENTS 105
8.2.3.2 SCALABLE REAGENTS 105
8.2.3.3 OTHERS 105
8.2.4 CONTROL KIT 105
8.2.5 OTHERS 105
8.3 INSTRUMENTS 105
8.3.1 ANALYZERS 106
8.3.2 SYSTEMS 106
8.3.3 OTHERS 107
8.4 SERVICES & SOFTWARE 107
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE 108
8.4.2 DPCR ANALYSIS SOFTWARE 108
8.4.3 CASTPCR ANALYSIS SOFTWARE 108
8.4.4 OTHERS 108
9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE 109
9.1 OVERVIEW 110
9.2 CIRCULATING TUMOR CELLS (CTCS) 113
9.3 CIRCULATING CELL-FREE DNA (CFDNA) 114
9.4 CELL-FREE RNA 115
9.5 EXOSOMES 116
9.6 EXTRACELLULAR VESICLES 117
9.7 OTHERS 118
10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE 119
10.1 OVERVIEW 120
10.2 BLOOD SAMPLE-BASED 123
10.3 URINE SAMPLE-BASED 124
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED 125
10.5 OTHERS 126
11 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE 127
11.1 OVERVIEW 128
11.2 MOLECULAR 131
11.2.1 NGS 132
11.2.2 PCR 132
11.2.3 MICROARRAY 132
11.2.4 PROTEOMICS 132
11.2.5 OTHERS 132
11.3 PROTEOMIC 132
11.3.1 NGS 133
11.3.2 PCR 133
11.3.3 MICROARRAY 133
11.3.4 PROTEOMICS 133
11.3.5 OTHERS 133
11.4 HISTOLOGY/IMAGING 134
12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE 135
12.1 OVERVIEW 136
12.2 CANCER APPLICATIONS 139
12.2.1 LUNG 140
12.2.2 BREAST 140
12.2.2.1 EARLY BREAST CANCER 140
12.2.2.2 ADVANCED BREAST CANCER 140
12.2.3 COLORECTAL 140
12.2.4 PROSTRATE 141
12.2.5 LIVER 141
12.2.6 OTHERS 141
12.3 NON-CANCER APPLICATIONS 141
12.3.1 PRENATAL DIAGNOSIS 142
12.3.2 PERSONALIZED IMMUNOTHERAPY 142
12.3.3 OTHERS 142
13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 143
13.1 OVERVIEW 144
13.2 ROUTINE SCREENING 147
13.3 THERAPY SELECTION 148
13.4 TREATMENT MONITORING 148
13.4.1 EARLY-STAGE DISEASE 149
13.4.2 LATE-STAGE/METASTATIC DISEASE 149
13.5 RECURRENCE MONITORING 150
13.6 PATIENT WORK-UP 150
13.7 OTHERS 151
14 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY 152
14.1 OVERVIEW 153
14.2 MULTI-GENE-PARALLEL ANALYSIS 156
14.3 SINGLE GENE ANALYSIS 157
15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER 158
15.1 OVERVIEW 159
15.2 HOSPITALS 162
15.3 REFERENCE LABORATORIES 162
15.4 DIAGNOSTIC CENTERS 163
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES 163
15.6 OTHERS 165
16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL 166
16.1 OVERVIEW 167
16.2 DIRECT TENDER 170
16.3 THIRD PARTY DISTRIBUTOR 170
16.4 OTHERS 171
17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY REGION 172
17.1 MIDDLE EAST AND AFRICA 173
17.1.1 SOUTH AFRICA 185
17.1.2 SAUDI ARABIA 192
17.1.3 U.A.E. 199
17.1.4 EGYPT 206
17.1.5 ISRAEL 213
17.1.6 REST OF MIDDLE EAST AND AFRICA 220
18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE 221
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 221
19 COMPANY PROFILE 222
19.1 F. HOFFMANN-LA ROCHE LTD. 222
19.1.1 COMPANY SNAPSHOT 222
19.1.2 REVENUE ANALYSIS 222
19.1.3 COMPANY SHARE ANALYSIS 223
19.1.4 PRODUCT PORTFOLIO 223
19.1.5 RECENT DEVELOPMENTS 223
19.2 GUARDANT HEALTH 224
19.2.1 COMPANY SNAPSHOT 224
19.2.2 REVENUE ANALYSIS 224
19.2.3 COMPANY SHARE ANALYSIS 225
19.2.4 PRODUCT PORTFOLIO 225
19.2.5 RECENT DEVELOPMENTS 225
19.3 THERMO FISHER SCIENTIFIC INC. 226
19.3.1 COMPANY SNAPSHOT 226
19.3.2 REVENUE ANALYSIS 226
19.3.3 COMPANY SHARE ANALYSIS 227
19.3.4 SWOT ANALYSIS 227
19.3.5 PRODUCT PORTFOLIO 228
19.3.6 RECENT DEVELOPMENTS 229
19.4 EXACT SCIENCE CORPORATION 230
19.4.1 COMPANY SNAPSHOT 230
19.4.2 REVENUE ANALYSIS 230
19.4.3 COMPANY SHARE ANALYSIS 231
19.4.4 PRODUCT PORTFOLIO 231
19.4.5 RECENT DEVELOPMENTS 231
19.5 QIAGEN 232
19.5.1 COMPANY SNAPSHOT 232
19.5.2 REVENUE ANALYSIS 232
19.5.3 COMPANY SHARE ANALYSIS 233
19.5.4 PRODUCT PORTFOLIO 233
19.5.5 RECENT DEVELOPMENTS 234
19.6 ANGLE PLC (2022) 235
19.6.1 COMPANY SNAPSHOT 235
19.6.2 REVENUE ANALYSIS 235
19.6.3 PRODUCT PORTFOLIO 236
19.6.4 RECENT DEVELOPMENT 236
19.7 BIOCEPT, INC. 237
19.7.1 COMPANY SNAPSHOT 237
19.7.2 REVENUE ANALYSIS 237
19.7.3 PRODUCT PORTFOLIO 238
19.7.4 RECENT DEVELOPMENT 238
19.8 BIO-RAD LABORATORIES, INC. (2022) 239
19.8.1 COMPANY SNAPSHOT 239
19.8.2 REVENUE ANALYSIS 239
19.8.3 PRODUCT PORTFOLIO 240
19.8.4 RECENT DEVELOPMENTS 240
19.9 EPIC SCIENCES 241
19.9.1 COMPANY SNAPSHOT 241
19.9.2 PRODUCT PORTFOLIO 241
19.9.3 RECENT DEVELOPMENTS 241
19.10 FLUXION BIOSCIENCES INC 242
19.10.1 COMPANY SNAPSHOT 242
19.10.2 PRODUCT PORTFOLIO 242
19.10.3 RECENT DEVELOPMENTS 242
19.11 ILLUMINA, INC. 243
19.11.1 COMPANY SNAPSHOT 243
19.11.2 REVENUE ANALYSIS 243
19.11.3 SWOT ANALYSIS 244
19.11.4 PRODUCT PORTFOLIO 244
19.11.5 RECENT DEVELOPMENT 244
19.12 JOHNSON & JOHNSON PRIVATE LIMITED 246
19.12.1 COMPANY SNAPSHOT 246
19.12.2 REVENUE ANALYSIS 246
19.12.3 SWOT ANALYSIS 247
19.12.4 PRODUCT PORTFOLIO 247
19.12.5 RECENT DEVELOPMENTS 247
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS 248
19.13.1 COMPANY SNAPSHOT 248
19.13.2 REVENUE ANALYSIS 248
19.13.3 SWOT ANALYSIS 249
19.13.4 PRODUCT PORTFOLIO 249
19.13.5 RECENT DEVELOPMENT 249
19.14 MDXHEALTH 250
19.14.1 COMPANY SNAPSHOT 250
19.14.2 REVENUE ANALYSIS 250
19.14.3 PRODUCT PORTFOLIO 251
19.14.4 RECENT DEVELOPMENTS 251
19.15 MENARINI SILICON BIOSYSTEMS 252
19.15.1 COMPANY SNAPSHOT 252
19.15.2 PRODUCT PORTFOLIO 252
19.15.3 RECENT DEVELOPMENTS 252
19.16 NATERA, INC. 253
19.16.1 COMPANY SNAPSHOT 253
19.16.2 REVENUE ANALYSIS 253
19.16.3 PRODUCT PORTFOLIO 254
19.16.4 RECENT DEVELOPMENTS 254
19.17 NEOGENOMICS LABORATORIES 255
19.17.1 COMPANY SNAPSHOT 255
19.17.2 REVENUE ANALYSIS 255
19.17.3 PRODUCT PORTFOLIO 256
19.17.4 RECENT DEVELOPMENTS 256
19.18 ONCOCYTE CORPORATION 257
19.18.1 COMPANY PROFILE 257
19.18.2 SERVICE PORTFOLIO 257
19.18.3 RECENT DEVELOPMENTS 257
19.19 PATHAI 258
19.19.1 COMPANY SNAPSHOT 258
19.19.2 PRODUCT PORTFOLIO 258
19.19.3 RECENT DEVELOPMENTS 258

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Data Bridge Market Research社の医療分野での最新刊レポート

本レポートと同じKEY WORD（biopsy）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.